Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
In patients with aromatic l-amino acid decarboxylase (AADC) deficiency, a decrease in catecholamines and serotonin levels in the brain leads to developmental delay and movement disorders. The beneficial effects of gene therapy in patients from 1 to 8 years of age with homogeneous severity of disease have been reported from Taiwan. We conducted an open-label phase 1/2 study of population including adolescent patients with different degrees of severity. Six patients were enrolled: four males (ages 4, 10, 15 and 19 years) and one female (age 12 years) with a severe phenotype who were not capable of voluntary movement or speech, and one female (age 5 years) with a moderate phenotype who could walk with support. The patients received a total of 2 × 1011 vector genomes of adeno-associated virus vector harbouring DDC via bilateral intraputaminal infusions. At up to 2 years after gene therapy, the motor function was remarkably improved in all patients. Three patients with the severe phenotype were able to stand with support, and one patient could walk with a walker, while the patient with the moderate phenotype could run and ride a bicycle. This moderate-phenotype patient also showed improvement in her mental function, being able to converse fluently and perform simple arithmetic. Dystonia disappeared and oculogyric crisis was markedly decreased in all patients. The patients exhibited transient choreic dyskinesia for a couple of months, but no adverse events caused by vector were observed. PET with 6-[18F]fluoro-l-m-tyrosine, a specific tracer for AADC, showed a persistently increased uptake in the broad areas of the putamen. In our study, older patients (>8 years of age) also showed improvement, although treatment was more effective in younger patients. The genetic background of our patients was heterogeneous, and some patients suspected of having remnant enzyme activity showed better improvement than the Taiwanese patients. In addition to the alleviation of motor symptoms, the cognitive and verbal functions were improved in a patient with the moderate phenotype. The restoration of dopamine synthesis in the putamen via gene transfer provides transformative medical benefit across all patient ages, genotypes, and disease severities included in this study, with the most pronounced improvements noted in moderate patients.10.1093/brain/awy331_video1awy331media15991361892001.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“two weaned off mechanical ventilation”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“four regained the ability to eat by mouth”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“Within 2 months, all had improvement in their voluntary movements”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
In the citing paper
“all showed improvements in dystonic episodes, irritability, and autonomic dysfunction.61”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional architecture of basal ganglia circuits: neural substrates of parallel processing
Alexander, G. E., & Crutcher, M. D. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90107-l · Cited by 4,131
Basal ganglia and cerebellar loops: motor and cognitive circuits
Middleton, F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00040-5 · Cited by 1,940
Modulation of Striatal Projection Systems by Dopamine
Gerfen, C. R., & Surmeier, D. J. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113641 · Cited by 1,718
Role of the Basal Ganglia in the Control of Purposive Saccadic Eye Movements
Hikosaka, O., Takikawa, Y., & Kawagoe, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.953 · Cited by 1,302 · cited 1×
“Cortico-basal ganglia loops, such as motor, prefrontal, limbic and oculomotor loops, have been proposed as functions of the basal ganglia (Alexander et al., 1990; Hikosaka et al., 2000; Middleton and Strick, 2000).”
BackgroundAdaptive segmentation of MRI data
Wells, W. M., Grimson, W. E. L., Kikinis, R., & Jolesz, F. A. (1996) · IEEE Transactions on Medical Imaging · doi:10.1109/42.511747 · Cited by 1,277
Dichotomous dopaminergic control of striatal synaptic plasticity
Shen, W., Flajolet, M., Greengard, P., & Surmeier, D. J. (2008) · Science · doi:10.1126/science.1160575 · Cited by 1,190 · cited 1×
“Dopamine is reported to play a role in synaptic plasticity, modulating glutamatergic neurons in order to enhance the synaptic connection to create a neuronal network (Calabresi et al., 2007; Shen et al., 2008).”
BackgroundSynaptic organisation of the basal ganglia
BOLAM, J. P., HANLEY, J. J., BOOTH, P. A. C., & BEVAN, M. D. (2000) · Journal of Anatomy · doi:10.1046/j.1469-7580.2000.19640527.x · Cited by 948 · cited 1×
“The main pathway for dopaminergic control of the motor function system is from the substantia nigra to the striatum (Bolam et al., 2000; Gerfen et al., 2011).”
BackgroundDopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865 · cited 1×
“Dopamine is reported to play a role in synaptic plasticity, modulating glutamatergic neurons in order to enhance the synaptic connection to create a neuronal network (Calabresi et al., 2007; Shen et al., 2008).”
BackgroundYung, K. K. L., Bolam, J. P., Smith, A. D., Hersch, S. M., Ciliax, B. J., & Levey, A. I. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00536-e · Cited by 542 · cited 1×
“Furthermore, as dopamine receptors are reported to exist all over the dendrites and not in the postsynaptic membrane alone, these receptors might be stimulated, thus allowing a sufficient dopamine effect to be obtained (Yung et al., 1995; Uchigashima et al., 2016).”
BackgroundHereditary progressive dystonia with marked diurnal fluctuation
Segawa, M., & Nomura, Y. (1991) · Key Topics in Brain Research · doi:10.1007/978-3-7091-9146-0_17 · Cited by 473
Maes, F., Vandermeulen, D., & Suetens, P. (1999) · Medical Image Analysis · doi:10.1016/s1361-8415(99)80030-9 · Cited by 397 · cited 1×
“This program provided manual and pointbased image registration as well as automated methods of grey value-based image registration, including a mutual information algorithm (Maes et al., 1999).”
MethodConstruction and validation of the Alberta Infant Motor Scale (AIMS).
Piper, M. C., Pinnell, L., Darrah, J., Maguire, T. O., & Byrne, P. J. (1992) · PubMed · Cited by 346
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344 · cited 6×
“Patients received infusions of the vector into two target points (one each into the bilateral putamen) by stereotactic surgery that was planned with the dedicated software program included with the StealthStation Treon Navigation System (FrameLink, Medtronic, Ireland) (Muramatsu et al., 2010).”
MethodInfluentialSelf-citationLong-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.005 · Cited by 282 · cited 1×
“This confirmed that the transduced DDC gene and production of AADC enzyme were maintained for long periods in neuronal cells with no cell division (Bankiewicz et al., 2006).”
BackgroundGene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
Hwu, W.-L., Muramatsu, S.-I., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H., Snyder, R. O., Byrne, B. J., Tai, C.-H., & Wu, R.-M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003640 · Cited by 246 · cited 5×
“The vector was then injected into the putamen bilaterally by a stereotactic operation (Hwu et al., 2012).”
BackgroundMethodResultInfluentialSelf-citationWassenberg, T., Molero-Luis, M., Jeltsch, K., Hoffmann, G. F., Assmann, B., Blau, N., Garcia-Cazorla, A., Artuch, R., Pons, R., Pearson, T. S., et al. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0522-z · Cited by 239
Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency
Brun, L., Ngu, L. H., Keng, W. T., Ch'ng, G. S., Choy, Y. S., Hwu, W. L., Lee, W. T., Willemsen, M. A. A. P., Verbeek, M. M., Wassenberg, T., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e620ae · Cited by 226 · cited 3×
“The main phenotype of AADC deficiency is movement disorder, including loss of voluntary movement, hypotonia, intermittent oculogyric crisis (OGC) and limb dystonia (Korenke et al., 1997; Brun et al., 2010).”
BackgroundSelf-citationMuramatsu, S.-I., Fujimoto, K.-I., Ikeguchi, K., Shizuma, N., Kawasaki, K., Ono, F., Shen, Y., Wang, L., Mizukami, H., Kume, A., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340252792486 · Cited by 187 · cited 1×
“In preclinical studies in a non-human primate model of Parkinson disease, more than 85–90% of transduced cells were medium spiny neurons (Muramatsu et al., 2002; Daadi et al., 2006).”
BackgroundSelf-citationPhD, K. H., Surtees, R. A. H., MD, C. R., & Clayton, P. T. (1992) · Neurology · doi:10.1212/wnl.42.10.1980 · Cited by 176 · cited 1×
“However, some relatively mild phenotypes have also been reported (Hyland et al., 1992; Swoboda et al., 2003; Tay et al., 2007; Leuzzi et al., 2015).”
BackgroundAromatic l -amino acid decarboxylase deficiency: Clinical features, treatment, and prognosis
Pons, R., Ford, B., Chiriboga, C. A., Clayton, P. T., Hinton, V., Hyland, K., Sharma, R., & De Vivo, D. C. (2004) · Neurology · doi:10.1212/wnl.62.7.1058 · Cited by 162 · cited 1×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundChien, Y.-H., Lee, N.-C., Tseng, S.-H., Tai, C.-H., Muramatsu, S.-I., Byrne, B. J., & Hwu, W.-L. (2017) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(17)30125-6 · Cited by 142
Self-citationSehara, Y., Fujimoto, K.-I., Ikeguchi, K., Katakai, Y., Ono, F., Takino, N., Ito, M., Ozawa, K., & Muramatsu, S.-I. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.010 · Cited by 141 · cited 1×
“The long-term enzyme expression was also observed in the post-mortem analysis of a monkey; AAV2-AADC that had been injected into the putamen was still detectable after 15 years (Sehara et al., 2017).”
BackgroundSelf-citationModels of Basal Ganglia Function and Pathophysiology of Movement Disorders
Wichmann, T., & DeLong, M. R. (1998) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(18)30261-4 · Cited by 137
Koyama, T., Osada, H., Tsujii, H., & Kurita, H. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01931.x · Cited by 136 · cited 1×
“The Kyoto Scale of Psychological Development 2001 was used to evaluate the mental status of the patients (Koyama et al., 2009; Aoki et al., 2016).”
MethodUchigashima, M., Ohtsuka, T., Kobayashi, K., & Watanabe, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514074113 · Cited by 125 · cited 1×
“Furthermore, as dopamine receptors are reported to exist all over the dendrites and not in the postsynaptic membrane alone, these receptors might be stimulated, thus allowing a sufficient dopamine effect to be obtained (Yung et al., 1995; Uchigashima et al., 2016).”
BackgroundAromatic l ‐amino acid decarboxylase deficiency: clinical features, drug therapy and follow‐up
Manegold, C., Hoffmann, G. F., Degen, I., Ikonomidou, H., Knust, A., Laass, M. W., Pritsch, M., Wilichowski, E., & Hörster, F. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1076-1 · Cited by 116 · cited 1×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundAromaticL-amino acid decarboxylase deficiency: Overview of clinical features and outcomes
Swoboda, K. J., Saul, J. P., McKenna, C. E., Speller, N. B., & Hyland, K. (2003) · Annals of Neurology · doi:10.1002/ana.10631 · Cited by 111 · cited 1×
“However, some relatively mild phenotypes have also been reported (Hyland et al., 1992; Swoboda et al., 2003; Tay et al., 2007; Leuzzi et al., 2015).”
BackgroundAromatic l-amino acid decarboxylase deficiency in Taiwan
Lee, H.-F., Tsai, C., Chi, C.-S., Chang, T., & Lee, H. (2008) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2008.03.008 · Cited by 89 · cited 2×
“The mutation IVS6+4A4T is a splice site mutation resulting in the formation of a truncated DDC protein (Lee et al., 2009).”
BackgroundAromatic L-Amino Acid Decarboxylase Deficiency: Diagnostic Methodology
Hyland, Κ., & Clayton, P. T. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.12.2405 · Cited by 87
Mimuro, J., Mizukami, H., Shima, M., Matsushita, T., Taki, M., Muto, S., Higasa, S., Sakai, M., Ohmori, T., Madoiwa, S., et al. (2014) · Journal of Medical Virology · doi:10.1002/jmv.23818 · Cited by 77
Self-citationMimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.258 · Cited by 74
Self-citationAromatic l-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma
Atwal, P. S., Donti, T., Cardon, A. L., Bacino, C. A., Sun, Q., Emrick, L., Sutton, V. R., & Elsea, S. H. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.04.008 · Cited by 59 · cited 1×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundKorenke, G. C., Christen, H. ‐., Hyland, Κ., HUNNEMAN, D. H., & Hanefeld, F. A. (1997) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(97)80065-7 · Cited by 57 · cited 1×
“The main phenotype of AADC deficiency is movement disorder, including loss of voluntary movement, hypotonia, intermittent oculogyric crisis (OGC) and limb dystonia (Korenke et al., 1997; Brun et al., 2010).”
BackgroundLeuzzi, V., Mastrangelo, M., Polizzi, A., Artiola, C., Kuilenburg, A. B. P., Carducci, C., Ruggieri, M., Barone, R. M. E., Tavazzi, B., Abeling, N. G. G. M., et al. (2014) · JIMD Reports · doi:10.1007/8904_2014_295 · Cited by 54 · cited 2×
“However, only patients with the moderate or mild phenotype respond to drugs—mainly dopamine agonists and MAOB inhibitors (Fiumara et al., 2002; Mastrangelo et al., 2013; Leuzzi et al., 2015)—with drug therapy providing little or no benefit for most severe patients (Hwu et al.”
BackgroundUnusually mild phenotype of AADC deficiency in 2 siblings
Tay, S. K. H., Poh, K. S. L., Hyland, Κ., Pang, Y. W., Ong, H. T., Low, P. S., & Goh, D. L. M. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.04.006 · Cited by 54 · cited 1×
“However, some relatively mild phenotypes have also been reported (Hyland et al., 1992; Swoboda et al., 2003; Tay et al., 2007; Leuzzi et al., 2015).”
BackgroundMontioli, R., Dindo, M., Giorgetti, A., Piccoli, S., Cellini, B., & Voltattorni, C. B. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu266 · Cited by 50 · cited 1×
“A relationship between the position of the mutation and the enzyme catalytic activity in AADC has been reported previously (Montioli et al., 2014).”
BackgroundAoki, S., Hashimoto, K., Ikeda, N., Takekoh, M., Fujiwara, T., Morisaki, N., Mezawa, H., Tachibana, Y., & Ohya, Y. (2015) · Brain and Development · doi:10.1016/j.braindev.2015.11.001 · Cited by 41 · cited 1×
“The Kyoto Scale of Psychological Development 2001 was used to evaluate the mental status of the patients (Koyama et al., 2009; Aoki et al., 2016).”
MethodNatural History of Aromatic l-Amino Acid Decarboxylase Deficiency in Taiwan
Hwu, W., Chien, Y., Lee, N., & Li, M. (2017) · JIMD Reports · doi:10.1007/8904_2017_54 · Cited by 41 · cited 4×
“The prevalence of AADC deficiency in the Taiwanese population is high because of the founder mutation IVS6+4A4T, and most Taiwanese patients present with the severe phenotype (Lee et al., 2009; Hwu et al., 2018).”
BackgroundInfluentialFiumara, A., Bräutigam, C., Hyland, Κ., Sharma, R., Lagae, L. G., Stoltenborg, B., Hoffmann, G. F., Jaeken, J., & Wevers, R. A. (2002) · Neuropediatrics · doi:10.1055/s-2002-34497 · Cited by 38 · cited 1×
“However, only patients with the moderate or mild phenotype respond to drugs—mainly dopamine agonists and MAOB inhibitors (Fiumara et al., 2002; Mastrangelo et al., 2013; Leuzzi et al., 2015)—with drug therapy providing little or no benefit for most severe patients (Hwu et al.”
BackgroundChen, P.-W., Lee, N., Chien, Y., Wu, J., Wang, P.-C., & Hwu, W. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.034 · Cited by 37 · cited 1×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundIto, S., Nakayama, T., Ide, S., Ito, Y., Oguni, H., Goto, Y., & Ōsawa, M. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.03094.x · Cited by 34 · cited 3×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundWidening Phenotypic Spectrum of AADC Deficiency, a Disorder of Dopamine and Serotonin Synthesis
Helman, G., Pappa, M. B., & Pearl, P. L. (2014) · JIMD Reports · doi:10.1007/8904_2014_327 · Cited by 33 · cited 1×
“Patients also present with autonomic dysfunction characterized by impairment of the sympathetic regulation of heart rate and blood pressure, excessive sweating and hyper-salivation, intellectual disability, hypoglycaemia, epilepsy, emotional instability and sleep disturbance (Hyland and Clayton, 1992; Brun et al., 201…”
BackgroundDistribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys
Daadi, M. M., Pivirotto, P., Bringas, J., Cunningham, J., Forsayeth, J., Eberling, J., & Bankiewicz, K. S. (2006) · NeuroReport · doi:10.1097/01.wnr.0000198952.38563.05 · Cited by 33 · cited 1×
“In preclinical studies in a non-human primate model of Parkinson disease, more than 85–90% of transduced cells were medium spiny neurons (Muramatsu et al., 2002; Daadi et al., 2006).”
BackgroundAromatic L-Amino Acid Decarboxylase Deficiency Is a Cause of Long-Fasting Hypoglycemia
Arnoux, J., Damaj, L., Napuri, S., Serre, V., Hubert, L., Cadoudal, M., Simard, G., Ceballos-Picot, I., Christa, L., & de Lonlay, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2740 · Cited by 32 · cited 2×
“…of heart rate and blood pressure, excessive sweating and hyper-salivation, intellectual disability, hypoglycaemia, epilepsy, emotional instability and sleep disturbance (Hyland and Clayton, 1992; Brun et al., 2010; Arnoux et al., 2013; Helman et al., 2014; Lee et al., 2014; Spitz et al., 2017).”
Background23 Hereditary progressive dystonia with marked diurnal fluctuation
Segawa, M. (2015) · Pediatric Neurology · doi:10.1159/000425356 · Cited by 31
Sanger, T. D. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.11.1509 · Cited by 29 · cited 2×
“In contrast to dystonia, excessive dopamine is considered to be involved in the course of dyskinesia (Wichmann et al., 1998; Sanger, 2003).”
BackgroundTransdermal rotigotine in the treatment of aromatic L ‐amino acid decarboxylase deficiency
Mastrangelo, M., Caputi, C., Galosi, S., Giannini, M. T., & Leuzzi, V. (2013) · Movement Disorders · doi:10.1002/mds.25303 · Cited by 25 · cited 1×
“However, only patients with the moderate or mild phenotype respond to drugs—mainly dopamine agonists and MAOB inhibitors (Fiumara et al., 2002; Mastrangelo et al., 2013; Leuzzi et al., 2015)—with drug therapy providing little or no benefit for most severe patients (Hwu et al.”
BackgroundSpitz, M., Nguyen, M. A., Roche, S., Héron, B., Milh, M., de Lonlay, P., Lion‐François, L., Testard, H., Napuri, S., Barth, M., et al. (2016) · JIMD Reports · doi:10.1007/8904_2016_550 · Cited by 24 · cited 1×
“Patients also present with autonomic dysfunction characterized by impairment of the sympathetic regulation of heart rate and blood pressure, excessive sweating and hyper-salivation, intellectual disability, hypoglycaemia, epilepsy, emotional instability and sleep disturbance (Hyland and Clayton, 1992; Brun et al., 201…”
BackgroundMicrostructural changes of brain in patients with aromatic L‐amino acid decarboxylase deficiency
Lee, W., Lin, J., Weng, W., & Peng, S. S. (2016) · Human Brain Mapping · doi:10.1002/hbm.23470 · Cited by 17 · cited 1×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundAbnormal glucose metabolism in aromatic l-amino acid decarboxylase deficiency
Ide, S., Sasaki, M., Kato, M., Shiihara, T., Kinoshita, S. N., Takahashi, J., & Goto, Y. (2009) · Brain and Development · doi:10.1016/j.braindev.2009.05.004 · Cited by 14 · cited 3×
“About 140 patients have been reported worldwide thus far (Hyland and Clayton, 1992; Pons et al., 2004; Ito et al., 2008; Manegold et al., 2009; Brun et al., 2010; Ide et al., 2010; Chen et al., 2014; Atwal et al., 2015; Kojima et al., 2016; Lee et al., 2017; Wassenberg et al., 2017).”
BackgroundSelf-citationA female case of aromatic l-amino acid decarboxylase deficiency responsive to MAO-B inhibition
Kojima, K., Anzai, R., Ohba, C., Goto, T., Miyauchi, A., Thöny, B., Saitsu, H., Matsumoto, N., Osaka, H., & Yamagata, T. (2016) · Brain and Development · doi:10.1016/j.braindev.2016.06.002 · Cited by 12 · cited 8×
“After MAOB inhibitor treatment was started, the patient gained the ability to walk unsteadily with support and to speak several words unclearly (Kojima et al., 2016).”
BackgroundMethodInfluentialSelf-citationLee, L., Cheung, K., Cheng, W., Ko, C., Lee, H. H., Ching, C., & Mak, C. M. (2014) · Hong Kong Medical Journal · doi:10.12809/hkmj133922 · Cited by 7 · cited 1×
“Patients also present with autonomic dysfunction characterized by impairment of the sympathetic regulation of heart rate and blood pressure, excessive sweating and hyper-salivation, intellectual disability, hypoglycaemia, epilepsy, emotional instability and sleep disturbance (Hyland and Clayton, 1992; Brun et al., 201…”
BackgroundWaldvogel (1999) · doi:10.1002/1531-8249(199907)46:1
Research works printed but not linked: 1
- Vitek, 1999, Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus, Ann Neurol, 46, 22, 10.1002/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z · doi:10.1002/1531-8249(199907)46:1<22::aid-ana6>3.0.co;2-z
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Within 2 months, all had improvement in their voluntary movements, two weaned off mechanical ventilation, four regained the ability to eat by mouth, and all showed improvements in dystonic episodes, irritability, and autonomic dysfunction.(61)”
BackgroundResultPearson, T. S., Gupta, N., San Sebastian, W., Imamura-Ching, J., Viehoever, A., Grijalvo-Perez, A., Fay, A. J., Seth, N., Lundy, S. M., Seo, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24524-8 · Cited by 186
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.005 · Cited by 162
“The increase in PDMS-2 total scores after eladocagene exuparvovec treatment had a negative correlation with age (Table S1), indicating that younger patients exhibited faster and greater improvements in PDMS-2 scores after gene therapy, a finding similar to previous publications.(16,18) This is likely related to a grea…”
Self-citationProkineticin-2 prevents neuronal cell deaths in a model of traumatic brain injury
Bao, Z., Liu, Y., Chen, B., Miao, Z., Tu, Y., Li, C., Chao, H., Ye, Y., Xu, X., Sun, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24469-y · Cited by 152
Metadata
- Authors
- Kojima, K., Nakajima, T., Taga, N., Miyauchi, A., Kato, M., Matsumoto, A., Ikeda, T., Nakamura, K., Kubota, T., Mizukami, H., Ono, S., Onuki, Y., Sato, T., Osaka, H., Muramatsu, S.-I., & Yamagata, T.
- Affiliations
- Jichi Medical University (JP)
- Yamagata University (JP)
- Anjo Kosei Hospital (JP)
- Utsunomiya Central Clinic, Utsunomiya, Tochigi, Japan
- Corresponding author
- Yamagata, Takanori
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-23
- Volume
- 142
- Issue
- 2
- Pages
- 322-333
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6377184
- OpenAlex
- W2912202854
- Cited by
- 139
- References
- 54
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 14 · 2023: 23 · 2022: 23 · 2021: 34 · 2020: 18 · 2019: 6
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Agency for Medical Research and Development
- AMED (JP17ek0109168)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- aromatic L-amino acid decarboxylase deficiency, gene therapy, adeno-associated virus vectors, motor function, cognitive function, dystonia, oculogyric crisis, dopamine synthesis, putamen, developmental delay, movement disorders
- MeSH terms
- Adolescent, Amino Acid Metabolism, Inborn Errors, Aromatic-L-Amino-Acid Decarboxylases, Brain, Child, Child, Preschool, Female, Humans, Male, Mental Processes, Motor Skills, Genetic Therapy, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.